Lasma LC Tablet contains Levocetirizine 5mg and Montelukast 10mg, combining an antihistamine and a leukotriene receptor antagonist to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria. Montelukast acts by blocking leukotriene D4 receptors in the respiratory tract, preventing bronchoconstriction, inflammation, and mucus production commonly associated with asthma and allergic rhinitis. This synergistic combination is indicated for the management of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in mild to moderate asthma. Lasma LC Tablet offers improved symptom control by targeting multiple pathways in the allergic response, enhancing patient compliance through once-daily dosing. It is generally well tolerated; however, clinicians should monitor for potential adverse effects such as headache, fatigue, gastrointestinal disturbances, or neuropsychiatric symptoms. Use in pregnancy and lactation should be under medical supervision. Dosage adjustments may be necessary in patients with hepatic or renal impairment. Lasma LC Tablet should be used as part of a comprehensive allergy management plan, including allergen avoidance and other pharmacotherapies as appropriate.